Overview
Adams Clinical conducts late-phase psychiatric and neurologic clinical trials under FDA rules, using double-blind, randomized, placebo-controlled designs for investigational drugs that have advanced past initial testing. Nine full-time doctors serve as neutral third parties to oversee trials and ensure unbiased results; data integrity comes from careful participant selection and rigorous rater training. The company provides external testing required by law (Chapter 21 CFR Part 54) for pharmaceutical companies seeking evidence of efficacy and safety, generating revenue from sponsors. With high academic standards and small, focused trial numbers in depression research, Adams Clinical aims to deliver reliable data to support regulatory decisions on new psychiatric and neurologic drugs.
Work here?Claim your company
Simplify's Take
What believers are saying
- InTandem Capital invested on 2024-05-21, bringing growth capital and healthcare-services expertise.
- The 2024-08-20 Bronx lease at Hutchinson Metro Center expands capacity in a dense patient market.
- Adams had 30-plus active openings in 2026-08-29, signaling commercial demand and network expansion.
What critics are saying
- Psychiatric trial recruitment failures can sink timelines, and Adams runs 38 open jobs in 2026.
- FDA audit findings or data-integrity lapses would jeopardize sponsor trust and future protocols.
- InTandem-backed growth pressures execution; one failed inpatient rollout could damage the whole network.
What makes Adams Clinical unique
- Adams Clinical spans six sites across four states as of 2026-07-28.
- Its 2024-12-11 InSite partnership adds inpatient schizophrenia and psychiatry trial capabilities.
- Adams emphasizes doctorate-level raters and physician oversight, reinforcing sponsor trust and data quality.
Help us improve and share your feedback! Did you find this helpful?